Overview

Efficacy and Safety of Pemafibrate for Nonalcoholic Fatty Liver Disease

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2026-03-01

Target enrollment:

Participant gender:

Summary

This is a study to evaluate the effect of pemafibrate on fatty liver in patients with hypertgemia combined with NAFLD, using fenofibrate as a control.

Phase:

PHASE2

Details

Lead Sponsor:

Yokohama City University

Treatments:

(R)-2-(3-((benzoxazol-2-yl-d4 (3-(4-methoxyphenoxy-d7)propyl)amino)methyl)phenoxy) butanoic acid
Fenofibrate